Literature DB >> 12560194

Post-kala-azar dermal leishmaniasis.

E E Zijlstra1, A M Musa, E A G Khalil, I M el-Hassan, A M el-Hassan.   

Abstract

Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL); it is characterised by a macular, maculopapular, and nodular rash in a patient who has recovered from VL and who is otherwise well. The rash usually starts around the mouth from where it spreads to other parts of the body depending on severity. It is mainly seen in Sudan and India where it follows treated VL in 50% and 5-10% of cases, respectively. Thus, it is largely restricted to areas where Leishmania donovani is the causative parasite. The interval at which PKDL follows VL is 0-6 months in Sudan and 2-3 years in India. PKDL probably has an important role in interepidemic periods of VL, acting as a reservoir for parasites. There is increasing evidence that the pathogenesis is largely immunologically mediated; high concentrations of interleukin 10 in the peripheral blood of VL patients predict the development of PKDL. During VL, interferon gamma is not produced by peripheral blood mononuclear cells (PBMC). After treatment of VL, PBMC start producing interferon gamma, which coincides with the appearance of PKDL lesions due to interferon-gamma-producing cells causing skin inflammation as a reaction to persisting parasites in the skin. Diagnosis is mainly clinical, but parasites can be seen by microscopy in smears with limited sensitivity. PCR and monoclonal antibodies may detect parasites in more than 80% of cases. Serological tests and the leishmanin skin test are of limited value. Treatment is always needed in Indian PKDL; in Sudan most cases will self cure but severe and chronic cases are treated. Sodium stibogluconate is given at 20 mg/kg for 2 months in Sudan and for 4 months in India. Liposomal amphotericine B seems effective; newer compounds such as miltefosine that can be administered orally or topically are of major potential interest. Although research has brought many new insights in pathogenesis and management of PKDL, several issues in particular in relation to control remain unsolved and deserve urgent attention.

Entities:  

Mesh:

Year:  2003        PMID: 12560194     DOI: 10.1016/s1473-3099(03)00517-6

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  159 in total

1.  Disseminated cutaneous leishmaniasis resembling post-kala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in Ethiopia.

Authors:  Tesfaye Gelanew; Zewdu Hurissa; Ermias Diro; Aysheshm Kassahun; Katrin Kuhls; Gabriele Schönian; Asrat Hailu
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Nested PCR assay for detection of Leishmania donovani in slit aspirates from post-kala-azar dermal Leishmaniasis Lesions.

Authors:  Gannavaram Sreenivas; N A Ansari; Joginder Kataria; Poonam Salotra
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

3.  Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India.

Authors:  Vidya Nand Rabi Das; Alok Ranjan; Krishna Pandey; Dharmendra Singh; Neena Verma; Sushmita Das; Chandra S Lal; Naresh K Sinha; Rakesh B Verma; Niyamat A Siddiqui; Pradeep Das
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

Review 4.  Diagnosis of visceral leishmaniasis.

Authors:  Pankaj Srivastava; Anand Dayama; Sanjana Mehrotra; Shyam Sundar
Journal:  Trans R Soc Trop Med Hyg       Date:  2010-11-11       Impact factor: 2.184

5.  Post Kala Azar dermal leishmaniasis in a 15-month-old Greek boy.

Authors:  D Doganis; M Mavrikou; M Tsolia
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

6.  Potential of direct agglutination test based on promastigote and amastigote antigens for serodiagnosis of post-kala-azar dermal leishmaniasis.

Authors:  Ruchi Singh; B V Subba Raju; R K Jain; Poonam Salotra
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

7.  A case of post kala-azar dermal leishmaniasis in India.

Authors:  Kalpalata Tripathy; Aparijita Misra; Rabinarayn Mallik; Debiprasad Misra; Niranjan Rout; Jayshree Rath
Journal:  Korean J Parasitol       Date:  2010-09-15       Impact factor: 1.341

8.  Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis.

Authors:  Matteo Rossi; Patrik Castiglioni; Mary-Anne Hartley; Remzi Onur Eren; Florence Prével; Chantal Desponds; Daniel T Utzschneider; Dietmar Zehn; Maria G Cusi; F Matthew Kuhlmann; Stephen M Beverley; Catherine Ronet; Nicolas Fasel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

Review 9.  Elimination of visceral leishmaniasis on the Indian subcontinent.

Authors:  Om Prakash Singh; Epco Hasker; Marleen Boelaert; Shyam Sundar
Journal:  Lancet Infect Dis       Date:  2016-09-28       Impact factor: 25.071

10.  Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.

Authors:  Samiran Saha; Tuhina Mazumdar; Khairul Anam; Rajesh Ravindran; Bibhas Bairagi; Bibhuti Saha; Ramapada Goswami; Netai Pramanik; Subhashis K Guha; Sourjya Kar; Dwijadas Banerjee; Nahid Ali
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.